Barinthus Biotherapeutics (BRNS) Competitors $0.91 -0.05 (-4.97%) As of 11:19 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. DMAC, ALMS, PRME, ALTS, DERM, INMB, PBYI, TLSA, NLTX, and SLNShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include DiaMedica Therapeutics (DMAC), Alumis (ALMS), Prime Medicine (PRME), Janone (ALTS), Journey Medical (DERM), INmune Bio (INMB), Puma Biotechnology (PBYI), Tiziana Life Sciences (TLSA), Neoleukin Therapeutics (NLTX), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors DiaMedica Therapeutics Alumis Prime Medicine Janone Journey Medical INmune Bio Puma Biotechnology Tiziana Life Sciences Neoleukin Therapeutics Silence Therapeutics Barinthus Biotherapeutics (NASDAQ:BRNS) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends. Do analysts rate BRNS or DMAC? Barinthus Biotherapeutics currently has a consensus price target of $5.17, suggesting a potential upside of 466.33%. DiaMedica Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 100.50%. Given Barinthus Biotherapeutics' higher possible upside, equities research analysts plainly believe Barinthus Biotherapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, BRNS or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Barinthus Biotherapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M2.46-$73.35M-$1.64-0.56DiaMedica TherapeuticsN/AN/A-$19.38M-$0.64-6.23 Is BRNS or DMAC more profitable? Barinthus Biotherapeutics' return on equity of -34.26% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -34.26% -29.30% DiaMedica Therapeutics N/A -43.67%-40.81% Which has more risk & volatility, BRNS or DMAC? Barinthus Biotherapeutics has a beta of -0.78, suggesting that its share price is 178% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Does the MarketBeat Community prefer BRNS or DMAC? DiaMedica Therapeutics received 78 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 62.91% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformBarinthus BiotherapeuticsOutperform Votes17100.00% Underperform VotesNo VotesDiaMedica TherapeuticsOutperform Votes9562.91% Underperform Votes5637.09% Do insiders & institutionals believe in BRNS or DMAC? 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 10.7% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer BRNS or DMAC? In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for DiaMedica Therapeutics and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.93 beat DiaMedica Therapeutics' score of 0.43 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Barinthus Biotherapeutics Positive DiaMedica Therapeutics Neutral SummaryBarinthus Biotherapeutics beats DiaMedica Therapeutics on 10 of the 15 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.80M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.618.8527.2320.02Price / Sales2.46256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book0.196.617.124.70Net Income-$73.35M$143.93M$3.23B$247.97M7 Day Performance-7.85%3.84%2.74%2.64%1 Month Performance-1.90%11.14%8.94%6.39%1 Year Performance-51.98%4.35%31.59%13.95% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.856 of 5 stars$0.91-5.0%$5.17+466.3%-46.1%$36.80M$14.97M-0.61107DMACDiaMedica Therapeutics1.3602 of 5 stars$4.09-1.9%$8.00+95.6%+54.4%$175.39MN/A-7.3020Short Interest ↑ALMSAlumis2.9216 of 5 stars$3.66+11.2%$24.86+579.2%N/A$172.83M$17.39M0.00N/APositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionHigh Trading VolumePRMEPrime Medicine3.6185 of 5 stars$1.31+10.1%$10.08+669.7%-79.4%$172.00M$3.85M-0.64234Positive NewsALTSJanoneN/A$9.73+8.0%N/AN/A$169.84M$18.05M0.00170News CoverageShort Interest ↑Gap DownDERMJourney Medical2.3209 of 5 stars$7.23-7.4%$9.88+36.6%+21.7%$168.43M$56.24M-7.6990Positive NewsShort Interest ↑INMBINmune Bio2.4286 of 5 stars$7.31+1.7%$22.80+211.9%-4.9%$168.01M$50K-3.3510News CoveragePositive NewsPBYIPuma Biotechnology4.138 of 5 stars$3.37+2.4%$7.00+107.7%+2.0%$167.26M$232.71M7.02200Positive NewsHigh Trading VolumeTLSATiziana Life Sciences1.2475 of 5 stars$1.43-0.7%N/A+47.5%$167.09MN/A0.008Gap UpNLTXNeoleukin TherapeuticsN/A$17.75+4.4%N/A-42.2%$166.81MN/A-5.7190High Trading VolumeSLNSilence Therapeutics3.0713 of 5 stars$5.56-3.0%$33.83+508.5%-74.9%$166.41M$27.70M-3.54100Positive News Related Companies and Tools Related Companies DMAC Competitors ALMS Competitors PRME Competitors ALTS Competitors DERM Competitors INMB Competitors PBYI Competitors TLSA Competitors NLTX Competitors SLN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BRNS Stock Free BRNS Stock Alerts